Skip to main content
. 2016 Jun 23;7(36):57737–57751. doi: 10.18632/oncotarget.10252

Figure 4. CD147 knockdown decreases cell viability in HER2-positive breast cancer in vitro after trastuzumab treatment.

Figure 4

A. Changes in the morphologies and numbers of HER2-positive cancer cells after treatment of SKBR3 and HCC1954 cells with 10 and 200 μg/mL trastuzumab, respectively, for 4 days (100× magnification). Note: a trastuzumab concentration of 0 μg/mL was used for the treatment with CD147 siRNA alone. B. Trastuzumab inhibition of cell viability, as measured by CCK-8 assay, occurred in a dose-dependent manner after 4 days of treatment with trastuzumab at five different concentrations. C. Trastuzumab inhibits cell viability in a time-dependent manner. The data are presented as the mean ± standard error of the mean (SEM) of three independent experiments. *p<0.05, **p<0.01 and ***p<0.001 vs. controls.